巨細胞病毒 (CMV)·單純皰疹病毒 (HSV) 檢驗:體外診斷市場分析·預測模式
Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)
|巨細胞病毒 (CMV)·單純皰疹病毒 (HSV) 檢驗:體外診斷市場分析·預測模式 Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)|
|出版日期: 2020年06月29日||內容資訊: 英文||
本報告提供全球主要39個國家的巨細胞病毒 (CMV) 及單純皰疹病毒 (HSV) 檢驗市場調查，提供市場及產品概要，主要產業趨勢，檢查數量，用戶數，新銷售數，平均銷售價格等各種資料及其轉變，彙整檢驗各種類的年度收益變化與預測，競爭環境與企業佔有率，分析師的各種分析等彙整資料。
Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact)
Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Cytomegalovirus Test market for the year 2020 and beyond. Cytomegalovirus (CMV) is a widely distributed pathogen that causes congenital infection worldwide. Groups that are at high risk for CMV include immunocompromised patients (AIDS patients or organ transplant recipients), premature infants, and newborns.
CMV represents the most common congenital, viral infection in the developed world and can cause neurological diseases as well as sensorineural deafness in children. Congenital CMV infections occur in children born to women with both primary and secondary CMV infections, meaning that pre-conceptional immunity does not protect against transmission of the virus during pregnancy.
Despite a lower risk of transmission, studies suggest that even in industrialized countries, the majority of congenital CMV infections are due to secondary (or non-primary) maternal infection, likely because a greater number of pregnancies occur in seropositive women. This model covers CMV test for pregnant women cases as well as Immuno compromised patients.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are -
Currently marketed Cytomegalovirus Tests and evolving competitive landscape -
Global, Regional and Country level market specific insights -
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: DiaSorin Spa, F. Hoffman-La Roche Ltd, Qiagen NV, Quidel Corp, bioMerieux SA, Bio-Rad Labs Inc. and Others
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -